Mycoplasma Testing in Clinical Market is Expected to Reach USD 526.23 Million by 2030
Global Mycoplasma Testing in Clinical Market business report is a wonderful guide to achieve an information or key data about market, emerging trends, product usage, motivating factors for customers, competitor strategies, brand positioning, customer preferences, and customer behaviour. Competitive analysis carried out in this market report puts forth the moves of the key players in the Healthcare industry such as new product launches, expansions, agreements, joint ventures, partnerships, and recent acquisitions. The key research methodology that has been employed here by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation.
According to the report “Mycoplasma genitalium Urethritis: Prevalence and Drug-Resistance Patterns” published in March 2020, Mycoplasma gentitalium is one of the leading causes of male urethritis, and according to a study conducted on a total of 914 participants, 28.7% of the population had Mycoplasma genitalium (MG) infection. According to the February 2019 news, Mycoplasma was isolated from the rectum and anal canal of Crohn’s disease patients, implying that Mycoplasma is also responsible for prevalent gastrointestinal infections.
Data Bridge Market Research analyses that the mycoplasma testing in clinical market which was USD 295.06 million in 2022, is expected to reach USD 526.23 million by 2030, at a CAGR of 7.5% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Download PDF Sample Report (Including Graphs, Charts, and List of Figures) @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-mycoplasma-testing-in-clinical-market&Shri
A mycoplasma test is used to identify an active or recent mycoplasma infection, which is a type of bacterial infection. Testing may be done in a variety of ways depending on which one is suspected, because there are different types of mycoplasma infections. The most common Mycoplasma is M. pneumoniae, which causes upper respiratory infections and can be tested with a blood sample. Other mycoplasma tests, may necessitate the collection of various types of samples, such as sputum, joint fluid, body fluids, tissue samples, or a genital swab.
Rising number of chronic diseases is expected to drive the market’s growth rate
Various infectious diseases are on the rise these days, owing to poor hygiene and a variety of other factors. Mycoplasma is known to cause a variety of diseases by attacking various bodily parts. Mycoplasma has been linked to urethritis, Crohn’s disease, pneumonia, and neurological disease, among other things. Because mycoplasma is the major cause of many diseases, the necessity for clinical testing is growing in order to provide the appropriate treatment at the right time. As a result, the increasing number of diseases is driving the expansion of worldwide mycoplasma testing in the clinical market.
Some of the major players operating in the mycoplasma testing in clinical market are:
- AB ANALITICA s.r.l. (Italy)
- BIOMÉRIEUX (France)
- ELITechGroup (France)
- Liofilchem S.r.l. (Italy)
- Agilent Technologies, Inc. (U.S.)
- PromoCell GmbH (Germany)
- F. Hoffmann-La Roche Ltd (Switzerland)
- OSANG Healthcare (South Korea)
- Sacace Biotechnologies Srl (Italy)
- Lonza (Switzerland)
- Merck KGaA (Germany)
- Seegene Inc. (South Korea)
- Clongen Laboratories, LLC (U.S.)
- Bio-Rad Laboratories, Inc. (U.S.)
- Charles River Laboratories (U.S.)
- Bionique Testing Laboratories LLC (U.S.)
- ZEAKON Diagnostics (India)
Report Scope and Market Segmentation
| REPORT METRIC | DETAILS |
| Forecast Period | 2023 to 2030 |
| Base Year | 2022 |
| Historic Years | 2021 (Customizable to 2015- 2020) |
| Quantitative Units | Revenue in USD Million, Volumes in Units, Pricing in USD |
Market Development
- In 2023, SwiftDx debuted a new mycoplasma detection kit in February. SwiftDx Mycoplasma Detection Kit, which was recently released, provides a faster and more convenient solution for detecting mycoplasma contamination using a lateral flow test.
- In 2020, Merck KGaA expanded its manufacturing presence in the United States in December, investing more than USD 45.6 million (EUR 40 million) in its Massachusetts and New Hampshire production sites. The sites were designed to generate a variety of biopharmaceutical manufacturing goods while also increasing the company’s production capacity.
- In 2020, Infinity Laboratories expanded its capabilities in April when it began offering Mycoplasma testing. The capacities of the top market players will improve as a consequence of the implementation of key strategies such as expansion, partnerships, acquisitions, and others, resulting in market expansion.
To Gain More Insights into the Market Analysis, Browse the Summary of the Research Report@ https://www.databridgemarketresearch.com/reports/global-mycoplasma-testing-in-clinical-market?Shri
The report provides insights on the following pointers:
- Market Penetration: Comprehensive information on the product portfolios of the top players in the this research report
- Product Development/Innovation: Detailed insights on upcoming technologies, R&D activities, and product launches in the market
- Competitive Assessment: In-depth assessment of the market strategies, and geographic and business segments of the leading players in the market
- Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies
Top Key Topics Covered:
- Strategic Imperatives
- Factors Creating Pressure on Growth
- The Strategic Imperative
- Growth Opportunities Fuel the Growth Pipeline Engine
- Research Methodology
- Scope and Segmentation
- Research Context and Scope of Analysis
- Segmentation
- Other Techniques for This Research Report Management
- Growth Opportunity Analysis
- Growth Drivers
- Growth Restraints
- Introduction
- The Impact of the COVID-19 Pandemic and Post
- Future Growth
- Innovation Ecosystem
Continued…
Segment Analysis:
Global mycoplasma testing in clinical market is categorized into four notable segments which are based on products, technique, disease area and end user.
- On the basis of products, the mycoplasma testing in clinical market is segmented into kits and reagents, instruments and services. In 2023, kits & reagents segment is expected to dominate the market with 54.31% market share because kits and reagents are repeatedly purchased as products for the detection of mycoplasma.
- On the basis of technique, the mycoplasma testing in clinical market is segmented into microbial culture techniques/direct assay, polymerase chain reaction, ELISA, DNA staining/ indirect assay, enzymatic methods. In 2023, microbial culture techniques/direct assay segment is expected to dominate the market with 36.42% market share because these techniques are cost effective and highly specific when a positive result is obtained.
- On the basis of disease area, the mycoplasma testing in clinical market is segmented into respiratory, urogenital, gastrointestinal, cardiovascular, musculoskeletal, and others. In 2023, the respiratory segment is expected to dominate the market with 36.37% because mycoplasma affects children & adults with mild to severe pneumonias.
The respiratory segment will dominate the disease area segment of the mycoplasma testing in clinical market
The respiratory segment will emerge as the dominating segment under disease area with approximately 37.00% market share. This is because of the growing number of infrastructural development activities in the market especially in the developing economies. Further, growth and expansion of the healthcare industry all around the globe will further bolster the growth of this segment.
- On the basis of end user, the mycoplasma testing in clinical market is segmented into hospitals and diagnostics laboratories. In 2023, diagnostics laboratories segment is expected to dominate the market with 55.14% market share because diagnostics laboratories are fully equipped with all the products required for the detection of mycoplasma and presence of skilled professional.
The diagnostics laboratories segment will dominate the end user segment of the mycoplasma testing in clinical market
The diagnostics laboratories centers segment will emerge as the dominating segment end user segment. This is because of the growing number of diagnostics laboratories in the market especially in the developing economies. Further, growth and expansion of research development services on a global scale will further bolster the growth of this segment.
Browse Detailed Summary of Research Report with TOC: https://www.databridgemarketresearch.com/toc/?dbmr=global-mycoplasma-testing-in-clinical-market&Shri
Some of the Most Important Questions Scrutinized in the Business Intelligence Report:
- What are the key growth parameters for this global market during the forecast period?
- Which key players are expected to hold the largest market share over the forecast period?
- Who are the leading vendors and manufacturers in this market?
- What are the key strategies adopted by leading players in the market for business development and geographical expansion?
- Which end-use industries can trigger high demand in the market over the forecast period?
- What are the key segments in this market?
- Which regional player will have anticipated leading the global market in terms of size?
- What is the impact of the novel coronavirus pandemic?
- Which obstacles must new players overcome in order to occupy a major position?
Top DBMR Healthcare Reports:
https://www.databridgemarketresearch.com/reports/global-cardasil-treatment-market?Shri
https://www.databridgemarketresearch.com/reports/global-aestheticcosmetic-lasers-market?Shri
https://www.databridgemarketresearch.com/reports/global-yeast-infection-market?Shri
About Data Bridge Market Research:
An absolute way to forecast what future holds is to comprehend the trend today!
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.
Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.
Contact Us:-
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Editor Details
-
Company:
- The Wire Times
